Tuberculosis (TB) treatment challenges in TB-diabetes comorbid patients: a systematic review and meta-analysis

Autor: Mahnoor Khattak, Anees ur Rehman, Tuba Muqaddas, Rabia Hussain, Muhammad Fawad Rasool, Zikria Saleem, Mesfer Safar Almalki, Samar Adel Alturkistani, Shuruq Zuhair Firash, Oseid Mohammed Alzahrani, Ammar Abdulraheem Bahauddin, Safa Almarzooky Abuhussain, Muath Fahmi Najjar, Hossameldeen Mahmoud Ali Elsabaa, Abdul Haseeb
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Annals of Medicine, Vol 56, Iss 1 (2024)
Druh dokumentu: article
ISSN: 07853890
1365-2060
0785-3890
DOI: 10.1080/07853890.2024.2313683
Popis: AbstractBackground The Directly Observed Treatment-Short Course (DOTS) Programme was implemented by WHO and includes a combination of four anti-tuberculosis (TB) drugs (isoniazid, pyrazinamide, ethambutol and rifampicin) for a period of six months to eradicate the TB infection completely. Diabetes mellitus (DM) is recognized as one of a strong contributor of TB according to World Health Organization (WHO). The presence of diabetes mellitus type 2 (DM type 2) makes TB treatment complicated. Thus, the objective of the current meta-analysis was to identify and quantify the impact of type 2 DM on treatment outcomes of TB patients treated under the DOTS Programme.Methods This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Through a systematic review of relevant literature, we focused on studies investigating treatment outcomes including extended treatment duration and recurrence for individuals with both TB and DM undergoing DOTS therapy. The extracted information included study designs, sample sizes, patient characteristics and reported treatment results.Results In 44 studies from different parts of the world, the pooled HR for the impact of DM on extended treatment duration and reoccurrence were HR 0.72, 95% CI 0.56–0.83, p
Databáze: Directory of Open Access Journals
Externí odkaz: